Today, Eli Lilly launched a four-dose, single-patient use KwikPen device for its injectable obesity drug, tirzepatide (Zepbound). The device gives patients an additional, potentially more convenient ...
Hosted on MSN
Eli Lilly’s Zepbound gets FDA OK for multi-dose pen
Eli Lilly received approval from the Food and Drug Administration for a label expansion of its weight-loss drug Zepbound, adding a new monthly delivery option for patients. The pharmaceutical company ...
Credit: Lilly. The 4-dose KwikPen device supports weight reduction in patients with obesity or overweight with weight-related conditions. The device is for single-patient use only and should never be ...
Used by millions of patients worldwide, the KwikPen® for single-patient use provides patients with a new option to receive Zepbound® Zepbound patients can access all doses in either multi-dose KwikPen ...
(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced that the U.S. FDA has approved its Epinephrine injection USP, 1 mg/mL, in both single-dose and multi-dose for use in U.S. hospitals.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results